Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 15/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 15/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056991 | 0.82 | POLB (0.38) | PDCD1CD274POLBTDP1RECQL | |
| SCHEMBL4265779 | 0.82 | CRHR1 (0.38) | PDCD1CD274POLBTDP1RECQL | |
| SCHEMBL6056988 | 0.81 | ALDH1A1 (0.36) | PDCD1CD274KDM4EMEN1MAPT | |
| SCHEMBL28725927 | 0.78 | TRPM8 (0.38) | PDCD1CD274POLBTDP1RECQL | |
| SCHEMBL11222083 | 0.74 | POLB (0.36) | PDCD1CD274POLBTDP1RECQL | |
| SCHEMBL6056936 | 0.73 | PDCD1 (0.48) | PDCD1CD274MEN1MAPTKMT2A | |
| SCHEMBL28048106 | 0.72 | PDCD1 (0.34) | PDCD1CD274POLBTDP1RECQL | |
| SCHEMBL4264185 | 0.71 | RECQL (0.40) | POLBTDP1RECQLKDM4EMEN1 | |
| SCHEMBL20894042 | 0.71 | CYP2D6 (0.35) | MEN1KMT2A | |
| SCHEMBL11223761 | 0.69 | SIRT6 (0.33) | PDCD1CD274POLBTDP1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982268-B2 | Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2006-01-03 | — | — | US | disclosed |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | NEUROGEN CORPORATION | 2003-11-27 | — | — | US | disclosed |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | NEUROGEN CORPORATION | 2003-11-27 | — | — | US | disclosed |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | NEUROGEN CORPORATION | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | GABRP, GABBR1, GABRA1 | PDCD1 810/4885CD274 972/4885POLB 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.